11 completed, 6 terminated, 1 enrolling by invitation, 1 withdrawn. 6 Phase 3, 6 Phase 4, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 4 | 6 | Terminated 3, Completed 2, Enrolling by invitation 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Oxacillin: new trials by email Literature Review of Oxacillin trials Research Report on Oxacillin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia | Phase 4 | Enrolling by invitation | West Virginia University | 300 | 2025-09-15 | 2026-09-17 |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis | Phase 4 | Terminated | West Virginia University | 5 | 2022-03-16 | 2026-05-05 |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Cefazolin, Dalbavancin, Daptomycin - Staphylococcal Bacteraemia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2021-04-22 | 2024-12-10 |
| Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan ciprofloxacin - Bacterial Infections, Antibiotic Resistant Infection | Completed | Yarmouk University | 24 | 2019-08-01 | 2021-11-04 | |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
| Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Dalbavancin, cefazolin, nafcillin, oxacillin or vancomycin - Osteomyelitis | Phase 3 | Withdrawn | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | 2016-03-01 | 2016-09-23 | |
| Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus Levofloxacin, Rifampicin, Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine - Infective Endocarditis | Phase 3 | Completed | University Hospital, Tours | 162 | 2016-02-29 | 2026-02-12 |
| A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial Telavancin, Vancomycin, Daptomycin - Bacteremia | Phase 3 | Terminated | Cumberland Pharmaceuticals | 121 | 2014-12-01 | 2020-02-17 |
| Patients Response to Early Switch To Oral:Osteomyelitis Study oral antibiotics, intravenous antibiotics - Osteomyelitis | Early Phase 1 | Terminated | Julio Ramirez | 11 | 2014-03-06 | 2021-04-06 |
| Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection CEM-102, IV or Oral standard of care antibiotics, Rifampin - Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee | Phase 2 | Terminated | Arrevus Inc. | 14 | 2012-12-01 | 2019-04-19 |
| Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Vancomycin - Bacteremia | Phase 2 | Completed | Duke University | 509 | 2011-02-01 | 2018-01-05 |
| Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment Vancomycin, Daptomycin, Semi-Synthetic Penicillin - Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 92 | 2010-04-19 | 2018-09-05 |
| Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs) - Infections | Phase 3 | Completed | Novartis Pharmaceuticals | 120 | 2010-03-01 | 2012-07-13 |
| Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections Daptomycin, Standard of Care (SOC) - Skin Diseases, Infectious | Phase 4 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 396 | 2008-07-23 | 2018-09-05 |
| Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci daptomycin, vancomycin, teicoplanin - Osteomyelitis | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 75 | 2007-06-26 | 2018-01-31 |
| Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia Amoxycillin/clavulanic acid, ceftriaxone/oxacillin - Community-Acquired Pneumonia | Phase 4 | Completed | UPECLIN HC FM Botucatu Unesp | 104 | 2005-04-01 | 2010-11-01 |
| Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin - Gram-Positive Bacterial Infections | Phase 2 | Completed | Cumberland Pharmaceuticals | 60 | 2003-08-01 | 2019-01-16 |
| Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria Linezolid, Vancomycin, Oxacillin - Bacterial Infections, Gram-Positive Bacterial Infections | Phase 3 | Completed | Pfizer | 739 | 2002-04-01 | 2009-09-14 |
Bacteremia (4) · Bacterial Infections (3) · Osteomyelitis (3) · Endocarditis (2) · Gram-Positive Bacterial Infections (2) · Soft Tissue Infections (2) · Staphylococcal Infections (2) · Cellulitis (1) · Community-Acquired Pneumonia (1) · Infections (1) · Pneumonia (1) · Renal Insufficiency (1) · Skin Diseases, Infectious (1) · Staphylococcal Skin Infections (1) · Surgical Wound Infection (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · West Virginia University (3) · Cumberland Pharmaceuticals (2) · AbbVie (1) · Arrevus Inc. (1) · Duke University (1) · Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) (1) · Julio Ramirez (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · UPECLIN HC FM Botucatu Unesp (1) · University Hospital, Tours (1) · Yarmouk University (1)
United States (13) · Russia (3) · Spain (3) · Brazil (2) · Panama (2) · Argentina (1) · Austria (1) · Belarus (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1) · France (1) · Georgia (1) · Germany (1)
Alena Jamdourek, MD (1) · Alistair Wheeler, MD (1) · Arif R Sawari, MD, MSc, MBA (1) · Arif R. Sarwari, MD, MSc, MBA (1) · Cristiane F Ribeiro, MD (1) · David Seligson, MD (1) · Ellie Hershberger (1) · Ellie Hershberger, Pharm.D. (1) · G. Ralph Corey, MD (1) · Joy J Juskowich, MD (1) · Joy J. Juskowich, MD (1) · Julio Ramirez, MD (1)
PMID 15276398, PMID 15840453, PMID 19588358, PMID 21829969, PMID 22530208, PMID 22908174, PMID 24884578, PMID 27682068, PMID 28202770, PMID 30264119, PMID 32665381, PMID 35578360, PMID 40802264, PMID 41419216, PMID 41999282, PMID 4902833, PMID 8948280
2009 (1), 2014 (1), 5UM1AI104681-12 (1)